CRYZP2

Across TCGA pan-cancer cohorts, CRYZP2 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated CRYZP2 data layer.

The strongest signal is observed in thyroid carcinoma (THCA), where higher CRYZP2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CRYZP2 expression acts as an unfavorable survival marker, although some lineages such as MESO and CESC show a favorable association.

THCA, ESCA, and LUSC are the cancer types where CRYZP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Tertile	IV	0.444	0.871	.001	45	view →
ESCA	OS	Tertile	IV	0.135	0.568	.031	36	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
STAD	OS	Quartile	III,IV	0.193	0.430	.010	33	view →
DLBC	OS	Tertile	All	0.696	0.948	.014	27	view →
MESO	DFS	Tertile	II,III,IV	0.706	0.192	.017	21	view →
UVM	OS	Tertile	III,IV	0.194	0.697	.008	18	view →
ACC	DFS	Tertile	All	0.365	0.648	.030	12	view →
THYM	OS	Tertile	All	0.700	0.973	.020	6	view →
CESC	OS	Tertile	All	0.956	0.781	.043	6	view →
SKCM	DFS	Quartile	IV	0.016	0.663	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

CRYZP2–THCA (OS)

Open the THCA breakdown →